Showing results (31-40 of 51) with videos related to
Sort By:
Pageof 6
European Journal of Cancer (Oxford, England : 1990)|August 4, 2021
Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational studyAngelyn Anton, Shirley Wong, Julia Shapiro, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2019
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate CancerAndrew J Armstrong, Russell Z Szmulewitz, Daniel P Petrylak, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 14, 2012
Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancerAndrew J Weickhardt, Tim J Price, Geoff Chong, et al.Asia-Pacific Journal of Clinical Oncology|September 24, 2020
Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive diseaseAndrew Schmidt, Angelyn Anton, Julia Shapiro, et al.BJUI Compass|May 2, 2022
Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancerAngelyn Anton, Sruti Pillai, Marie Christine Semira, et al.European Urology Open Science|October 3, 2022
Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell CarcinomaCristian Udovicich, Jason Callahan, Mathias Bressel, et al.European Urology Focus|November 11, 2020
Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to ProstatectomyNattakorn Dhiantravan, John Violet, Renu Eapen, et al.The Journal of Urology|December 28, 2020
Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc AnalysesAndrew J Armstrong, Neal D Shore, Russell Z Szmulewitz, et al.BJU International|October 8, 2021
Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancerRichard Kelly, Angelyn Anton, Shirley Wong, et al.The Prostate|June 8, 2022
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroupsArnulf Stenzl, Russell Z Szmulewitz, Daniel Petrylak, et al.Pageof 6